TABLE 2.
PDAE among Infants Exposed to Cefepime, Piperacillin/Tazobactam, or Tobramycin using MIC Susceptibility Breakpoints for Enterobacteriaceae & P. aeruginosa
| Antibiotic | Organism | MIC (mcg/mL) | PDAE (hours)a | % Patients Achieving Time Above MIC | ||
|---|---|---|---|---|---|---|
| 1x Dosing Interval after Discontinuation | 2x Dosing Interval after Discontinuation | 3x Dosing Interval after Discontinuation | ||||
| Cefepime | P. aeruginosa | 8 | 26 ± 17 (3, 69) | 58.5 | 18.2 | 8.1 |
| Enterobacteriaceae | 2 | 54 ± 23 (6, 95) | 79.9 | 38.8 | 18.4 | |
| 1 | 68 ± 25 (7, 104) | 84.7 | 49.0 | 25.2 | ||
| Piperacillin/ tazobactam | Enterobacteriaceae & P. aeruginosa | 16 | 19 ± 8 (7, 36) | 72.6 | 8.2 | 2.2 |
| Enterobacteriaceae | 8 | 25 ± 9 (9, 44) | 85.0 | 12.5 | 4.3 | |
| Tobramycin | P. aeruginosa & Enterobacteriaceae | 2 | 19 ± 7 (10, 36) | 18.0 | 0.2 | 0 |
| P. aeruginosa & Enterobacteriaceae | 1 | 28 ± 9 (15, 52) | 59.1 | 3.6 | 0.1 | |
a
Numbers, except for sample size, represent mean ± standard deviation with 95% confidence interval in parentheses.
MIC, minimum inhibitory concentration; PDAE, post-discontinuation antibiotic exposure.